The Effects of SARS-CoV-2 Pandemic on the Distribution of Secondary Bacterial Pneumonia Agents and Antibiotic Resistance Profile in Intensive Care Units

İsmail Selçuk Aygar
{"title":"The Effects of SARS-CoV-2 Pandemic on the Distribution of Secondary Bacterial Pneumonia Agents and Antibiotic Resistance Profile in Intensive Care Units","authors":"İsmail Selçuk Aygar","doi":"10.54584/lms.2023.34","DOIUrl":null,"url":null,"abstract":"Since the World Health Organization declared COVID-19 (Coronavirus Disease 2019) a pandemic on March 11, 2020, SARS-CoV-2 has caused high rates of morbidity and mortality worldwide. The addition of secondary bacterial infections such as pneumonia to the clinical course led to more mortality of the disease. This situation has led to an increase in the use of antibiotics for both prophylactic and therapeutic purposes and has caused concerns about the increase in antibiotic resistance rates and multi-drug resistant strains. 679 COVID-19 patients (Group 1) with a diagnosis confirmed by polymerase chain reaction (PCR) and 366 patients who were followed up in the anesthesia intensive care unit (ICU) during the pandemic but had negative SARS-CoV-2 PCR test results (Group 2) were included in this study; all of them were treated in the ICU of our hospital between April 2020 - May 2022. In order to observe the possible effects of SARS-CoV-2 infection on the distribution of the causative agent and changes in antibiotic resistance patterns, the data of 363 patients (Group 3) who were treated in the anesthesia ICU between April 2017 and May 2019 (pre-pandemic period) were analyzed. Bacterial agents isolated from tracheal aspirate samples and antibiotic resistance rates of 1408 patients in the groups were determined. Pathogenic microorganism growth was detected in the tracheal aspirate samples of 430 (63.3%) of the patients followed in the COVID-19 ICUs. In the patients followed in COVID-19 ICUs, as secondary bacterial pneumonia agents, in order of frequency; Acinetobacter baumannii (39.6%), Klebsiella pneumoniae (35.5%) and Pseudomonas aeruginosa (3.5%) were isolated. A. baumannii and K. pneumoniae isolation rates were significantly higher in COVID-19 patients (Group 1) compared to non-COVID-19 ICU patients (Group 2) and were similarly higher in all patients in the pandemic period (Group 1 + Group 2) compared to the pre-epidemic period (p<0.001). Other remarkable findings were the presence of high antibiotic resistance rates in A. baumannii and K. pneumoniae strains isolated during the pandemic period, compared to the pre-pandemic period, and the observation of multi-drug resistance in the vast majority of isolates. In order to prevent the increased risk of mortality associated with concomitant secondary bacterial infections in patients followed in ICUs due to COVID-19; It is important to evaluate patients quickly in terms of bacterial infections, to take timely and appropriate antibiotic treatment and to take necessary isolation measures.","PeriodicalId":344016,"journal":{"name":"Life and Medical Sciences","volume":"17 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life and Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54584/lms.2023.34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Since the World Health Organization declared COVID-19 (Coronavirus Disease 2019) a pandemic on March 11, 2020, SARS-CoV-2 has caused high rates of morbidity and mortality worldwide. The addition of secondary bacterial infections such as pneumonia to the clinical course led to more mortality of the disease. This situation has led to an increase in the use of antibiotics for both prophylactic and therapeutic purposes and has caused concerns about the increase in antibiotic resistance rates and multi-drug resistant strains. 679 COVID-19 patients (Group 1) with a diagnosis confirmed by polymerase chain reaction (PCR) and 366 patients who were followed up in the anesthesia intensive care unit (ICU) during the pandemic but had negative SARS-CoV-2 PCR test results (Group 2) were included in this study; all of them were treated in the ICU of our hospital between April 2020 - May 2022. In order to observe the possible effects of SARS-CoV-2 infection on the distribution of the causative agent and changes in antibiotic resistance patterns, the data of 363 patients (Group 3) who were treated in the anesthesia ICU between April 2017 and May 2019 (pre-pandemic period) were analyzed. Bacterial agents isolated from tracheal aspirate samples and antibiotic resistance rates of 1408 patients in the groups were determined. Pathogenic microorganism growth was detected in the tracheal aspirate samples of 430 (63.3%) of the patients followed in the COVID-19 ICUs. In the patients followed in COVID-19 ICUs, as secondary bacterial pneumonia agents, in order of frequency; Acinetobacter baumannii (39.6%), Klebsiella pneumoniae (35.5%) and Pseudomonas aeruginosa (3.5%) were isolated. A. baumannii and K. pneumoniae isolation rates were significantly higher in COVID-19 patients (Group 1) compared to non-COVID-19 ICU patients (Group 2) and were similarly higher in all patients in the pandemic period (Group 1 + Group 2) compared to the pre-epidemic period (p<0.001). Other remarkable findings were the presence of high antibiotic resistance rates in A. baumannii and K. pneumoniae strains isolated during the pandemic period, compared to the pre-pandemic period, and the observation of multi-drug resistance in the vast majority of isolates. In order to prevent the increased risk of mortality associated with concomitant secondary bacterial infections in patients followed in ICUs due to COVID-19; It is important to evaluate patients quickly in terms of bacterial infections, to take timely and appropriate antibiotic treatment and to take necessary isolation measures.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
SARS-CoV-2大流行对重症监护病房继发性细菌性肺炎病原体分布及抗生素耐药性的影响
自世界卫生组织于2020年3月11日宣布COVID-19(冠状病毒病2019)大流行以来,SARS-CoV-2在全球范围内造成了很高的发病率和死亡率。继发性细菌感染(如肺炎)在临床病程中的增加导致该病的死亡率增加。这种情况导致抗生素用于预防和治疗目的的增加,并引起了对抗生素耐药率和多重耐药菌株增加的关注。本研究纳入679例经聚合酶链反应(PCR)确诊的COVID-19患者(第一组)和366例大流行期间在麻醉重症监护病房(ICU)随访但SARS-CoV-2 PCR检测结果阴性的患者(第二组);所有患者均于2020年4月至2022年5月在我院ICU接受治疗。为观察SARS-CoV-2感染对病原菌分布和抗生素耐药模式变化的可能影响,对2017年4月至2019年5月(大流行前)在麻醉ICU治疗的363例患者(第3组)进行数据分析。测定各组1408例患者气管吸入标本中分离的细菌菌剂及抗生素耐药率。在新冠肺炎重症监护病房随访的患者中,430例(63.3%)气管吸入标本中检出病原微生物生长。在COVID-19重症监护病房随访的患者中,继发性细菌性肺炎病原体的出现频率依次为;检出鲍曼不动杆菌(39.6%)、肺炎克雷伯菌(35.5%)和铜绿假单胞菌(3.5%)。与非COVID-19 ICU患者(2组)相比,COVID-19患者(1组)的鲍曼不动杆菌和肺炎克雷伯菌分离率显著高于非COVID-19 ICU患者(2组),大流行期间(1组+ 2组)所有患者的鲍曼不动杆菌和肺炎克雷伯菌分离率均高于流行前(p<0.001)。其他值得注意的发现是,与大流行前相比,在大流行期间分离的鲍曼不动杆菌和肺炎克雷伯菌菌株存在较高的抗生素耐药率,并且在绝大多数分离株中观察到多重耐药性。为了防止因COVID-19而在icu随访的患者并发继发性细菌感染相关的死亡风险增加;重要的是迅速评估患者的细菌感染情况,及时采取适当的抗生素治疗,并采取必要的隔离措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Evaluation of the Serum Zinc Level in Patients Followed in Hospital with the Diagnosis of COVID-19 in Samsun Province, Türkiye Choosing Wisely in Immunology Laboratory: Reviewing of Antinuclear Antibody (ANA) Test Requests and Results Together with Other Tests Incidence and Imaging of Colorectal Cancer Between 2015-2020 in Somalia: A Review of 585 Colonoscopy A 6-Year Review of the Electronic Drug Prescription System in the Republic of Türkiye Utilization Rate of Primary Health Services in the Diagnosis, Treatment, and Follow-Up of Patients Diagnosed with Rheumatic Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1